Mandolin, founded in 2024 and based in San Francisco, operates an AI automation platform that targets one of healthcare's most administratively burdensome areas: specialty drug access. The platform deploys AI agents capable of reasoning, clicking, calling, and following up to handle the end-to-end lifecycle of specialty drug administration. This includes intake, benefits verification, prior authorizations, and revenue cycle management, replacing fragmented manual workflows with automated processes that integrate directly with electronic health records (EHRs), payer portals, and manufacturer hubs.
The company's technology spans AI automation, AI agents, and healthcare workflow automation. Its platform currently covers more than $10 billion in drug spend across the United States, reflecting significant operational scale within the specialty pharmaceutical sector.
Mandolin has raised $40 million in combined seed and Series A funding. The company operates within the broader healthcare vertical, with a focus on specialty drug administration and improving patient access to therapies.
